Serotonin (5-hydroxytryptamine, 5-HT) is a potent biogenic amine, first described as the vasoconstrictor compound contained in the serum and later identified as a neurotransmitter 1 .
Once synthesized in the gastrointestinal tract, peripheral serotonin is actively incorporated by platelets which store the amine within their dense granules. As a result, serotonin is widely distributed in the body through the blood flow. Under normal physiological conditions, platelet granule-stored 5-HT can be either delivered into blood flow through the open canalicular system or exposed to the platelet mitochondrial monoamine oxidase (MAO). In the latter case, it is degraded into 5-hydroxyindole acetic acid (5-HIAA) which also passes through the open canalicular system towards blood. However, the platelet storage of serotonin occurs against such a high concentration gradient that it protects the organism from serotonininduced vascular tone abrupt modifications, maintains the serotonin plasma level in the low nM range and prevents the amine of being degraded.
Degradation of serotonin mainly occurs through monoamine oxidases (MAOs). There are two MAO isoforms: MAO-A preferentially degrades endogenous bioamines such as serotonin and norepinephrine, and MAO-B preferentially degrades exogenous bioamines such as phenylethylamine and benzylamine 2 . These specificities are relative however. Human platelets and lymphocytes contain only the MAO-B isoform. Human MAOA and MAOB genes are both located on the short arm of the X chromosome (Xp.11.4-11.3). The two genes are arranged in a tail-to-tail orientation, and both span at least 60 kb, consist of 15 exons, and exhibit an identical exon-intron organization 2 .
Serotonin has been proposed to be predictive of coronary artery diseases especially in young people 3 . In addition, inhibitors of 5-HT incorporation, the so-called specific serotonin reuptake inhibitors (SSRIs) used as major depression therapy 4 , reduce the cardiovascular complications of these patients by inhibiting platelet activation and aggregation 5 . We therefore decided to measure the platelet serotonin level and to study its catabolism in a series 4 of untreated men at low risk for cardiovascular disease. Unexpectedly, the greatest modifications in serotonin catabolism were found in former smokers (FS) rather than in current smokers (S) as compared to patients who had never smoked (NS). We found that smoking induced an epigenetic regulation of MAOB, i.e. a reduction of its gene promoter methylation, resulting in high MAO amounts which persist long after (over 10 years) quitting smoking.
RESULTS

Characteristics of patients
With the aim to study the impact of smoking on platelet activation, independently of other cardiovascular risk factors such as diabetes and hormonal factors, the men population was carefully selected as untreated and free of any major cardiovascular risk. The clinical profile of the studied population in relation with the smoking status is shown in Table 1 and site, and more specifically one or more femoral plaque(s) was significantly higher in the S group than in the FS and NS groups (P < 0.01).
Supplementary
Platelet aggregation, platelet 5-HT and plasma 5-hydroxyindole acetic acid (5-HIAA)
Because, so far, most studies dealing with smoking have compared S and NS, we initially considered only two groups, i.e. current smokers [S] and presently-non-smokers who had not smoked for at least one year on the day of blood sampling (including never smokers [NS] and former smokers [FS] ). In response to 2 μg/ml collagen, platelet aggregation amplitude in whole blood was similar in the two groups (16 ± 5 vs. 16 ± 4 ohms), whereas the aggregation velocity (ohms.min -1 ) was significantly lower (P < 0.01) in smokers (7.9 ± 0.5) than in presently-non-smokers (10.3 ± 0.6). The platelet 5-HT content was almost identical in the two groups (S and NS + FS), as was plasma 5-HIAA, the main 5-HT catabolite (Fig. 1a,b) .
This surprising lack of differences between current smokers (S) and presently-non-smokers (NS + FS) prompted us to further analyze NS + FS in order to differentiate those who had never smoked (NS) from those who had smoked but had quitted one year ago or more, i.e.
former smokers (FS). The less rapid aggregation of smokers' platelets was confirmed (velocity 7.9 ± 0.5 ohms.min -1 for S vs. 10 ± 0.6 and 11 ± 1 for FS and NS respectively, P < 0.01), indicating that platelet aggregation velocity was back to normal after quitting smoking.
The discrimination of FS in the non-smoking group allowed us to evidence that FS had a significantly reduced platelet amount of 5-HT as compared to NS and S (Fig. 1a) . We thus hypothesized that 5-HT was released from the storage granules of FS platelets and, once released, was degraded into 5-HIAA. Indeed, the 5-HIAA amounts measured in FS plasmas were significantly higher than in NS and S (Fig. 1b) .
Platelet monoamine oxidase
The fact that platelet 5-HT was more degraded into 5-HIAA suggested that the enzyme responsible for this degradation, MAO, was either more active or more abundant in FS. We thus measured both MAO activity and MAO amount in platelets, the most easily accessible source of MAO. As previously reported 2, 7, 8 , we confirmed that MAO-B (the only isoenzyme present in human platelets) activity was significantly weaker in current smokers than in presently-non-smokers (Fig. 1c) . But when discriminating FS in the non smoking group, MAO-B activity was found at a similar level in S and NS, whereas it was significantly greater in FS (Fig. 1c) .
This high platelet MAO activity found in FS was explained by a higher MAO-B amount than in NS as assessed by both binding and western blot (Fig. 1d) . Unexpectedly however, the platelet MAO amount was also high in S (Fig. 1d) . This prompted us to calculate for each donor the enzyme catalytic activity, i.e. the ratio of MAO-B activity to its amount. This evidenced that the lowest mean MAO-B catalytic activity was that of S platelets where one enzyme molecule hydrolyzed 9,000 molecules of substrate per hour as compared to NS (13,000) and FS (11,000). Platelet 5-HT and plasma 5-HIAA levels were highly correlated (P<0.001, not shown) with both platelet MAO activities and amounts.
The present results reassert that MAO-B activity is inhibited by smoking and reveal for the first time that (i) platelet MAO-B amount increased during smoking and (ii) this increase lasted long after quitting smoking (13 yrs average in our group of FS).
Methylation of the MAO gene promoter
The platelet MAO-B amount remaining elevated several years after quitting smoking suggested a smoking-induced gene modification. A detailed analysis reported that the human MAOB core promoter contains 22 CpG sites that can be methylated, with methylation reducing the transcription of MAOB 9 . We therefore analyzed the methylation patterns of the MAOB core promoter in a new series (5 S, 4 FS, 4 NS) clinically identical to the initial cohort (Supplementary Table 2 ). As for the previous population, the MAO-B amount was the lowest in NS patients, whereas the MAO-B activity was higher in FS (Fig. 2 insert) .
DNA analysis was performed on peripheral blood mononuclear cells (PBMC) of S, FS and NS subjects, which exhibited similar MAO profiles as platelets (Supplementary Fig. 1 ). The methylation frequency was notably higher for NS, both at each of the 22 sites (Fig. 2a, left) or as the mean of the 22 sites (Fig. 2a, right) . According to the repressing effect of DNA methylation upon general gene transcription 10 and upon specific transcription of the human MAOB 9 , the individual methylation frequencies were negatively correlated with the platelet MAO-B amounts of the 13 studied patients (Fig. 2b) . These findings bring an explanation for the high MAO-B amount long-lasting after quitting smoking.
In addition, in order to verify that tobacco smoke is truly responsible for this methylation change, DNA methyltransferase and nucleic acid demethylase activities were measured in lung nuclear extracts of mice exposed to cigarette smoke. Interestingly, these mice exhibited lung MAO profiles (MAO-B and MAO-A, Fig. 3a ) comparable to those found in human S patient's platelets, i.e. higher amounts and lower activity in Sm than in "non-smoking" mice (NSm). Noteworthy, the MAO profile of mice platelets (MAO-B, Fig. 3 insert) was also comparable. The lung DNA methyltransferase activity appeared not significantly different ( Fig. 3b) , whereas the nucleic acid demethylase activity was significantly higher in "smoking" mice (Sm, Fig. 3c ). Moreover, the in vitro nucleic acid demethylase activity of mouse lung nuclear extracts was increased by harman and norharman, two known inhibitors of MAO activities present in tobacco smoke 11, 12 . This demethylase activity increase was of 12.3 ± 0.4 and 9.6 ± 0.5 % for harman and norharman (100 nM), respectively (n = 3).
DISCUSSION
The present report is one of the very few to differentiate former smokers (FS) from those who have never smoked in terms of platelet 5-HT catabolism. We showed that the 5-HT content was significantly reduced in platelets of FS who had quitted smoking for a mean of 13 years.
This smoking-induced long-lasting effect was due to demethylation of the MAOB gene promoter which resulted in a persisting high platelet MAO-B amount. Moreover, such results obtained in two species (human and mice), with three cell types (platelets, PBMC, lung cells) and concerning two MAO isoenzymes, indicate that this smoking-induced MAO gene deregulation could have a more general impact than vascular modifications.
Platelets from smokers were reported to show increased aggregability 13 and to be more prone to spontaneous aggregation 14 . Platelet aggregation was, however, studied with platelet rich plasma or isolated platelets. Under similar conditions, we could not find any difference (not shown), the sensitivity of the turbidimetric method being too low. Platelet aggregation has also often been measured after acute smoking of 1-3 cigarettes, accounting for some discrepancies in the literature. Here, we measured platelet aggregation in whole blood, i.e. in the physiological platelet environment which might differ from one group to the other. Fitting with a trend for a higher fibrinogen plasma level (Supplementary Table 1 ) and thus a higher blood viscosity in S 15 , the collagen-induced aggregation velocity was significantly lower for S than for NS and FS. This result emphasizes the importance of studying platelet functions in whole blood.
Platelet activation was reported for both acute and chronic smokers with more activation markers exposed on platelet surface 16, 17 . The present results suggest that this smoking-induced platelet activation may not be sufficient to release the stored 5-HT from dense granules since it was found similar in platelets from S or NS. Only FS platelets had lower levels of 5-HT, a finding fitting with the deficiency of the vesicular monoamine transporter reported in platelets of smokers 18 leading to a platelet dense granule 5-HT storage defect. Accordingly, we found a higher 5-HIAA level in FS plasma. The untransformed 5-HT dispersed from platelet to plasma is largely diluted, and plasma 5-HT concentrations were not significantly different between the three groups (not shown).
To account for the higher level of 5-HIAA in FS plasma, platelet MAO-B could be either more active or in higher quantity, inasmuch that we did not find any difference in other possible 5-HT metabolites (sulfo-and nitro(so)-conjugates, not shown). So far, MAO-B activity was repeatedly reported to be lower in current smokers than in non smokers 2, 7, 8, 19 .
Here, we report that the FS group accounts for the significantly higher platelet MAO-B activity found in "presently-non-smokers". More noticeably, the platelet MAO amount was elevated in FS and also in S. One could thus expect that more MAO-B protein would result in high MAO-B activity in the two groups. Yet, this was only true for FS but not for S. By calculating the MAO-B catalytic activity, we found that the lowest was that of S platelets, reasserting the low MAO-B activity of current smokers 2, 7, 8 . This is consistent with the fact that MAOs are oxygen-dependent and carbon monoxide-inhibited enzymes 2 . This inhibition of MAO-B catalytic activity during smoking is also in agreement with PET-scan data obtained with brain 19 and peripheral organs 20 of smokers, non-smokers and ex-smokers using a radiotracer which binds irreversibly to MAO-B: on average MAO-B is inhibited by over 40% in smokers vs. non-smokers with no significant difference between brains of non-and ex-smokers. Two reports assessing whether MAO inhibition could recover after an overnight abstinence 21 or after 10-31 days of smoking abstinence 22 led to the conclusions that (i) the enzyme is irreversibly inhibited by compounds in cigarette smoke, and (ii) after smoking cessation, MAO activity probably returns to normal through de novo synthesis of the enzyme.
Our present report not only confirms but enlarges and promotes these two deductions with the elucidation of the mechanism regulating MAO-B inhibition and slow recovery.
We showed here that MAO activity was inhibited during smoking and restored after quitting, whereas MAO amount was increased during smoking and remained high many years after quitting. From a mechanistic point of view, the persistence of increased amounts of MAO-B was unexpected, even though some haematological and inflammation characteristics remain modified for several years after quitting smoking 6, 23, 24 . Modifications regarding the gene encoding MAO-B might bring a new explanation. Three recent studies identify an association between genetic variation on chromosome 15, in a region containing the gene encoding the nicotinic acetylcholine receptor, and risk of lung cancer [25] [26] [27] . A SNP is clearly linked to smoking quantity level 26 . Here we demonstrated how epigenetics may also participate to tobacco addiction and its long-lasting effects after quiting. A higher methylation of MAOA was found associated with nicotine-and alcohol-dependence 29 in women whereas a downregulation of MAOA transcription was reported in several cancers including lung cancer 28 .
Here we found that both S and FS exhibited a reduced methylation of the MAOB promoter, leading to a more active transcription of the gene and hence a higher MAO-B amount.
Moreover, our ex vivo animal experiments showing that tobacco smoke induced an increase of nucleic acid demethylase activity give support to the fact that reduction in the MAOB promoter methylation is actually due to smoking. This is the first report showing that smoking has a long-lasting effect in modifying MAOB transcription. So far, the latter had only been shown during the differentiation of a human colon adenocarcinoma cell line 9 . DNA methylation is a covalent modification associated with long-term gene silencing and potential links to tumorigenesis 10 and suicide 30 . Thus, the epigenetic process found in the present report, which regulate gene activity without altering the DNA code, might explain at least some of the reported long-lasting effects and health problems generated by smoking 6, 23, 24 . Now, the nucleic acid demethylase activity, which we found increased by tobacco smoke, generates aldehydes 31, 32 (Fig. 4) . The latter are able to further cyclize bioamines, and from 5-HT to generate, among others, β-carbolines such as harman or norharman 2, 11, 12 . Smoking periods might, thus, keep the MAO inhibited, contributing to a sustained 5-HT neurotransmission, and therefore mimicking an antidepressant effect (Fig. 4) . In addition, being inverse agonists of GABA-A receptors, β-carbolines are involved in mood regulation and more precisely in anxious states. Accordingly, several data indicate that tobacco smoke is an anti-depressive addict 2, 8, 33 . About half of the patients studied here were submitted to an anxiety-depression questionnaire (not shown). All of these were underscored, i.e. below the characteristic threshold scores for depression and anxiety, indicating that none of the evaluated patients was presenting with any patent anxio-depressive disease. As previously reported 22, 33 , we observed that the S group was the most proned to depression. One can therefore speculate that smokers, instead of using a MAO inhibitor or another antidepressant, need to inhibit their MAO by smoking. In this context, epigenetic modifications have been reported for psychiatric disorders in animal models 34 . Our present finding is the first report of an epigenetic modification in human smokers.
In conclusion, as it is increasingly evident that 5-HT is at the crossroads of cardiovascular and depressive diseases 35 , we suggest that MAO could be a determinant player at this crosssection (Supplementary data including Supplementary Fig. 2 ) as it is already for alcoholic addiction 36 and for predisposition to lung cancer 26, 28 . Ultrasound Investigation. Ultrasonography was performed by experienced sonographer physicians using a 7.5 MHz probe for the extracranial carotid and femoral arteries and a 3-MHz probe for the abdominal aorta, as previously described 38 . At each of the three sites, data were classified into two categories: absence of any atherosclerotic plaque and presence of one or more arterial plaque(s), regardless of the precise location and number. The intima media thickness (IMT) was measured on the common carotid artery on both sides in the far wall of at least 1 cm of longitudinal length, and calculated by a program as previously described 39 .
Platelet, PBMC and plasma preparation, platelet aggregation. Blood was drawn from antecubital veins of fasting subjects in 3.8 % sodium citrate-anticoagulated tubes (1:10 v/v).
Whole blood aggregometry was measured using 500 µL aliquots of blood diluted 1: DNA methyltransferase and nucleic acid demethylase activities of mouse lung. Male A/J mice, aged 6 to 8 weeks, were purchased from Charles River (Orléans, F) and allowed to acclimate for 2 weeks before the start of the study. Mice were exposed to filtered air or mainstream cigarette smoke (10 mice in each group) using the exposure regimen developed by Witschi et al. 45 at a concentration of 250 mg/m 3 for 5.5 hours/day, 5 days/week for 5 months, and sacrificed. Nuclear extracts were prepared from lungs according to the protocol of Dignam et al. 46 . Their DNA methyltransferase activity was determined as described previously 47 . The β-carbolines also act on GABA-A receptors, thus contributing to mood regulation as do MAO and 5-HT. Noteworthy, the MTHFR activity does not appear to be the limiting step in this process since folates were not significantly different between smokers and non smokers (cf. supplementary Table 1 ).
*The in vivo levels of plasma harman (6.8 nM) and norharman (20.02 nM) reported in smokers 48 might, however, be high enough to affect nucleic acid demethylase activity, as it is the case for platelet MAO-B inhibition 48 .
